ArticleGynecologic oncology reports2026
Sentinel node technologies in low-resource settings: Current evidence and future perspectives.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To review the role of sentinel lymph node (SLN) mapping in gynecologic oncology, with emphasis on its feasibility, challenges, and future perspectives in low- and middle-income countries (LMICs). Methods: A narrative review of the literature was conducted, including prospective and retrospective trials, systematic reviews, international guidelines, and regional experiences in LMICs published between 2000 and 2025. The search was performed using PubMed, Scopus, and Web of Science. Results: SLN mapping provides accurate staging with reduced morbidity compared to systematic lymphadenectomy. Already known ultrastaging improves detection of micrometastases (MICs) and isolated tumor cells (ITCs), thereby refining nodal staging and prognostic stratification. Indocyanine green (ICG) demonstrates the highest detection rates, but its cost and the need for near-infrared imaging limit access in LMICs. Alternatives such as blue dyes, technetium-99 m, carbon nanoparticles, and superparamagnetic iron oxide (SPIO) offer variable performance and feasibility. Regional experiences from Latin America, Africa, and Asia confirm that simplified protocols, accessible tracers, and cooperative training programs enable safe and effective SLN implementation. Key obstacles include cost, tracer availability, lack of ultrastaging, surgical learning curves, and limited infrastructure. Emerging solutions involve portable fluorescence devices, SPIO, cost-effective carbon tracers, telepathology, and international mentoring. Conclusion: SLN mapping represents a cornerstone of precision surgical staging in gynecologic oncology already known. In LMICs, its equitable implementation will depend on accessible tracers, portable fluorescence technologies, and sustained international collaboration, collectively advancing global health equity in cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.